|
Clinical characteristics of the patients in immunohistochemistry analyses |
|||||
| Non-smokers |
Smokers |
COPD st I–II |
COPD st IV |
p-value |
|
|
|
|||||
| Total (n) |
9 |
10 |
10 |
16 |
|
| Male/Female |
2/7 |
9/1 |
7/3 |
10/6 |
|
| Age (years) |
66 (13) |
62 (7) |
60 (8) |
54 (7) |
|
| Pack years |
0 |
51 (11) |
32 (18) |
29 (17) |
p < 0.0001 |
| FEV1 (l) |
2.7 (1.4) |
3.0 (0.8) |
2.4 (0.8) |
0.6 (0.3) |
p < 0.0001 |
| FEV1 (% of ref) |
104 (16) |
85 (10) |
73 (13) |
20 (10) |
p < 0.0001 |
| FEV1/FVC (%) |
85 (10) |
79 (7) |
70 (12) |
34 (9) |
p < 0.0001 |
| DCO (% of ref) |
91 (18) |
79 (15) |
69 (13) |
25 (8) |
p < 0.0001 |
| DCO/VA (% of ref) |
90 (12) |
83 (12) |
71 (14) |
37 (10) |
p < 0.0001 |
|
Data is shown as mean (SD), as % of reference where applicable. None of the patients with stage I–II disease were on oral or inhaled corticosteroids. All patients with stage IV COPD had inhaled corticosteroid (below 1 mg). None of the patients were on N-acetylcysteine or vitamins. No one had previous asbestos exposure. | |||||
Peltoniemi et al. Respiratory Research 2006 7:133 doi:10.1186/1465-9921-7-133 |
|||||